# PolyPid Ltd (PYPD)

- Sector: Healthcare · Industry: Biotechnology
- SEC CIK: 0001611842 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001611842))
- Full page: https://inspectstocks.com/stocks/pypd
- Data as of: price 2026-09-28; newest filing used 2026-08-12; latest fiscal period ended 2026-06-30

## Grade

Not rated: fewer than four of the five checks could be answered from the filings. This is not the same as a failing grade.

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Net income, trailing twelve months | $31.5M |
| Free cash flow, trailing twelve months | -$28.1M |
| Return on equity | 287.1% |
| Debt to equity | 0.25 |
| Diluted EPS, trailing twelve months | $2.09 |
| Share price | $5.34 |
| Market value | $97.2M |
| Price / earnings | 2.6x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/pypd)
- [Financial statements](https://inspectstocks.com/stocks/pypd/financials)
- [Competitors](https://inspectstocks.com/stocks/pypd/peers)
- [Earnings](https://inspectstocks.com/stocks/pypd/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.